LEADER 03958nam  2200793z- 450 
001 9910557287803321
005 20231214133146.0
035   $a(CKB)5400000000041162
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68938
035   $a(EXLCZ)995400000000041162
100   $a20202105d2020      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aAntimicrobial Resistance in Horses
210   $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020
215   $a1 electronic resource (124 p.)
311   $a3-03936-712-9 
311   $a3-03936-713-7 
330   $aAntimicrobial resistance (AMR) is a global problem with extremely complex epidemiology involving the direct and indirect transmission of antibiotic resistant pathogens and mobile genetic elements between humans, animals, and the environment. AMR is, therefore, recognized as a ?One Health? issue. Data that describe AMR prevalence and trends are required to enable the judicious and prudent use of antimicrobials in animals, which has implications both from veterinary and animal welfare aspects as well as from a zoonotic and public health perspective. Horses are a potential reservoir of AMR for humans due to close human?animal contact, as was demonstrated with shared human and horse methicillin-resistant Staphylococcus aureus (MRSA) strains causing outbreaks in equine hospitals. Extended-spectrum beta-lactamase-producing Enterobacteriaceae, considered as clinically and economically important to the AMR burden in human and veterinary medicine, has been reported in both community and clinic equine populations. Strains of Enterobacteriaceae pose a major worldwide threat due to the geographical expansion of ESBL-producing clones as well as the horizontal interspecies dissemination of ESBL-encoding plasmids and genes. In human medicine, ESBL-E infection is associated with increased morbidity, mortality, length of hospital stay, delay of targeted appropriate treatment, and higher costs. These issues also need to be addressed in horses. This Special Issue on AMR in horses encompasses several papers that describe the prevalence, risk factors, and molecular data on MDR bacteria in healthy horses in Canada, Japan, Spain, and Israel, in addition to papers that describe the clinical impact of MDR bacteria in diseased horses in Austria, USA, France and Israel.
606   $aHumanities$2bicssc
606   $aSocial interaction$2bicssc
610   $aequine
610   $afoal
610   $aESBL-E
610   $aantibiotic resistance
610   $ashedding
610   $aumbilical infection
610   $arisk factors
610   $ahealthy horses
610   $astaphylococci
610   $aMSSA
610   $aST1640
610   $alukPQ
610   $aESBL
610   $aEscherichia coli
610   $aEnterobacteriaceae
610   $aantimicrobial resistance
610   $aCTX-M-1
610   $aSHV
610   $afarm
610   $aESBL-E acquisition
610   $aAmpC
610   $aKlebsiella pneumoniae
610   $aantibiotic-resistance
610   $a?-lactamases
610   $ahorses
610   $aextended-spectrum ?-lactamase
610   $aAmpC ?-lactamase
610   $ahorse
610   $amultidrug resistance
610   $abeta-lactamase
610   $acephalosporinase
610   $amicrobiota
610   $aNorth America
610   $ahorse pathogens
610   $aepidemiology
615  7$aHumanities
615  7$aSocial interaction
700   $aSteinman$b Amir$4edt$01293810
702   $aNavon-Venezia$b Shiri$4edt
702   $aSteinman$b Amir$4oth
702   $aNavon-Venezia$b Shiri$4oth
906   $aBOOK
912   $a9910557287803321
996   $aAntimicrobial Resistance in Horses$93022735
997   $aUNINA